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Abstract: Chronic obstructive pulmonary disease (COPD) is a leading cause of disability and 
mortality. Caring for patients with COPD, particularly those with advanced disease who experi-
ence frequent exacerbations, places a significant burden on health care budgets, and there is a 
global need to reduce the financial and personal burden of COPD. Evolving scientific evidence on 
the natural history and clinical course of COPD has fuelled a fundamental shift in our approach 
to the disease. The emergence of data highlighting the heterogeneity in rate of lung function 
decline has altered our perception of disease progression in COPD and our understanding of 
appropriate strategies for the management of stable disease. These data have demonstrated that 
early, effective, and prolonged bronchodilation has the potential to slow the rate of decline in 
lung function and to reduce the frequency of exacerbations that contribute to functional decline. 
The goals of therapy for COPD are no longer confined to controlling symptoms, reducing exac-
erbations, and maintaining quality of life, and slowing disease progression is now becoming an 
achievable aim. A challenge for the future will be to capitalize on these observations by improving 
the identification and diagnosis of patients with COPD early in the course of their disease, so 
that effective interventions can be introduced before the more advanced, disabling, and costly 
stages of the disease. Here we critically review emerging data that underpin the advances in 
our understanding of the clinical course and management of COPD, and evaluate both current 
and emerging pharmacologic options for effective maintenance treatment.
Keywords: COPD, chronic obstructive pulmonary disease, long-acting bronchodilator, early 
treatment
Introduction
Chronic obstructive pulmonary disease (COPD) is a leading cause of disability and 
death worldwide, with population prevalence rates of 5%–13%.1–3 Prevalence rates 
are related directly to tobacco smoking and indoor air pollution, and are expected to 
rise as smoking rates continue to increase, notably among women and in developing 
countries.1,4 By 2030, COPD is expected to represent the third leading cause of death 
in middle-income countries.4 In addition, COPD accounts for a significant proportion 
of health care budgets, with the majority of costs being attributed to hospitalizations 
for exacerbations.5 Thus, there is a global drive to improve COPD diagnosis and 
management to reduce personal and economic burden.
COPD is characterized by airflow limitation and inflammation, resulting in progres-
sive decline in respiratory function and quality of life (QoL); patients with COPD face 
a significantly increased risk for premature death.6 The pathologic effects of COPD on 
the respiratory system are pervasive, affecting the proximal and peripheral airways, International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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lung parenchyma, and pulmonary vasculature.7 The clini-
cal course of COPD may be punctuated by exacerbations 
that can be life-threatening and associated with worsening 
outcomes, including increased mortality risk and resource 
utilization.8,9 Moreover, comorbid conditions such as 
cardiovascular disease, diabetes mellitus, and depression, 
as well as associated systemic consequences, including 
weight loss and muscle dysfunction due to inactivity and 
deconditioning, add considerably to the overall burden of 
disease.9,10
COPD is considered to be preventable and treatable,1 
yet, despite its high prevalence and significant burden, it 
remains substantially underdiagnosed and undertreated.11,12 
Undiagnosed early-stage patients, especially if they are 
symptomatic, are more likely to progress to a more severe 
form of COPD that impacts further on QoL and increases 
health care costs.12,13
In this article, we draw together the latest   understanding 
of COPD and evaluate current and potential future approaches 
to long-term treatment.
Methods
A rigorous, directed approach was adopted to identify relevant 
published literature. PubMed.gov (http://www.ncbi.nlm.nih.gov/
sites/entrez) was searched using the following terms: “COPD” 
AND “burden, prevalence”, “clinical course”, “lung function 
decline”, “progression”, “exacerbation, recovery”, “treatment 
guidelines”, “early treatment”, “maintenance”, “GOLD”, 
“long-acting bronchodilator”, “long-acting beta-agonist”, “long-
acting anticholinergic”, “muscarinic antagonist”, and “inhaled 
corticosteroids”. The search was limited to articles published 
in English. Given the volume of literature available relating to 
the etiology, pathophysiology, and management of COPD, key 
terms were restricted to publication titles as follows: “course”, 
“decline”, “progression”, “exacerbation”, “guidelines”, “early”, 
“maintenance”, “GOLD”, and “exacerbation”.
Many national and international respiratory societies 
have developed guidelines for COPD management.1,14–16 
Guideline discussion focuses principally on the internation-
ally recognized Global Initiative for Chronic Obstructive 
Lung Disease (GOLD) guidelines,1 upon which many local 
guidelines are based.
The review of emerging treatment options focuses on 
pharmacotherapeutic agents recently approved or submitted 
to regulatory authorities for approval, including indacaterol 
and roflumilast. The long-acting anticholinergic aclidinium 
bromide is also discussed. PubMed.gov search terms for 
these agents were “COPD” AND “[drug name]”.
Major respiratory congress abstract databases (American 
Thoracic Society and European Respiratory Society) were 
also searched from 2007 to 2009. Additional literature was 
identified by hand-searching reference listings of the publica-
tions identified using the approach outlined above.
Evolving concepts of lung function 
decline
The clinical course of COPD has been viewed as a progres-
sive decline in lung function over time (measured in terms of 
forced expiratory volume in one second [FEV1]).17 However, 
recent work suggests that disease progression may not be 
uniform and that not all patients follow the same clinical 
course. Furthermore, in addition to smoking, other clinical 
factors, such as the presence of symptoms, are important in 
COPD progression.
Evidence from the Framingham cohort13 and large-scale 
interventional trials18,19 reinforce earlier work   demonstrating 
that annual rates of decline not only differ according to smok-
ing status17 but, importantly, also appear to be greater during 
the earlier disease stages. In light of these observations, the 
Framingham cohort authors have offered an alternative view 
of disease progression that highlights the heterogeneity of 
the rate of lung function decline in the context of smoking 
history (Figure 1 and accompanying table).13 In contrast 
with the Fletcher–Peto study,17 the Framingham population 
includes both men and women, a wide age range (13–71 
years), and both working and nonworking participants.   
It also included close attention to symptoms and a longi-
tudinal follow-up of 23 years.13 Although changes in lung 
function from adolescence to old age differ in males and 
females, analysis of the Framingham cohort revealed similar 
increases in the rate of FEV1 decline in both sexes, and ben-
eficial effects of   smoking cessation with age, notably among 
early quitters.13 Also noteworthy (and in contrast with the 
observations of Fletcher and Peto),17 symptomatic patients 
represented a susceptible group for progressive lung function 
decline, reinforcing current thinking that multidimensional 
influences impact COPD progression and that early diagno-
sis and intervention are critical. As such, COPD phenotyping 
and its impact on disease progression are areas of intense 
research.20–22 Symptom status also appeared to contribute 
to the rate of lung function decline among a cohort of 519 
patients with GOLD Stage I disease at baseline (accord-
ing to prebronchodilator spirometry), in that patients with 
symptomatic disease had a faster decline in FEV1, increased 
respiratory care utilization, and lower QoL compared with 
those with asymptomatic disease at baseline.23International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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These latter observations highlight the potential for early 
treatment intervention to relieve dyspnea and thereby maintain 
or even improve the capacity for physical activity,24 which has 
been shown to decline during the early disease stages.25 The 
need for early diagnosis to facilitate early interventions is 
further underscored by the close relationship between physical 
activity and clinical functional status.26 Among a cohort of 341 
COPD patients hospitalized with a first exacerbation, higher 
levels of physical activity were associated with significantly 
higher diffusing capacity of the lung for carbon monoxide, 
expiratory muscle strength, six-minute walking distance, and 
maximal oxygen uptake.26 In addition, more physically active 
patients appeared to have reduced systemic inflammation.26 
etc Taken together, these data suggest that early diagnosis and 
interventions to facilitate sustained physical activity could 
potentially slow disease progression.
Role of exacerbations
Exacerbation frequency appears to exert a negative impact on 
progressive lung function decline, at least in ex-smokers.27,28 
Among a cohort of 109 COPD patients, frequent exacerbators 
had a significantly faster decline in FEV1 (−40.1 mL/year) 
and peak expiratory flow (−2.9 L/min/year) compared with 
infrequent exacerbators (−32.1 mL/year and −0.7 L/min/year, 
respectively).27   Similarly, in a separate study in 102 patients 
with COPD, the annual rate of decline in FEV1 was signifi-
cantly higher among frequent versus infrequent exacerbators 
(P = 0.017).28
As COPD progresses, exacerbations become more 
frequent.27,29,30 Donaldson et al reported that patients with 
severe COPD (GOLD Stage III) had an annual exacerba-
tion frequency of 3.43 compared with 2.68 for patients with 
moderate COPD (GOLD Stage II, P = 0.029).27
Recent evidence also extends our knowledge of recovery 
following acute exacerbations. Patients experiencing an 
acute exacerbation remain at increased risk for subsequent 
exacerbations during the recovery phase,31 and are markedly 
inactive during and after hospitalization.32 Indeed, exacerba-
tions tend to occur in clusters, and the two months   following 
an initial exacerbation represent a high-risk period for sub-
sequent exacerbations.33 Some patients also fail to regain 
their pre-exacerbation symptomatic status.31,34 Such patients 
appear to experience a persistently heightened inflammatory 
state.31,35 The rate of lung function decline for these patients 
has yet to be evaluated, although it has been shown that higher 
mortality rates are associated with exacerbations.
Current approaches  
to managing COPD
The internationally recognized GOLD guidelines were 
developed to increase awareness of COPD and to provide 
up-to-date information on management approaches.1 Several 
national guidelines have been issued and are in broad agree-
ment with the GOLD guidelines.14–16 In the UK, National 
Institute for Health and Clinical Excellence (NICE) guide-
lines are currently being updated based on recent evidence of 
clinical and cost effectiveness of treatment options.
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Figure 1 effects of smoking and smoking cessation on decline in lung function 
among A male and B female adults with chronic obstructive lung disease.13 
Notes: *P , 0.05 versus healthy never-smokers;  #P , 0.05 versus continuous 
smokers.
Abbreviations: NS, never smokers (solid line); CS, continuous smokers (dashed 
line, long); Q , 30, smokers who quit before the age of 30 years (dashed line, 
short);  Q30–40,  smokers  who  quit  between  the  ages  of  30  and  40  years 
(dotted line); Q40+, smokers who quit after the age of 40 years (dot-dash line). 
A  prospective  evaluation  of  lung  function  (Fev1)  over  time  (median  follow-up 
23  years)  in  the  Framingham  Offspring  cohort  with  two  or  more  spirometry 
measurements during follow-up (n = 4391) indicated marked differences in the   
rate of lung function decline according to smoking status. Panel A illustrates the 
decline in Fev1 over time among men and Panel B illustrates the decline in Fev1 over 
time among women. 
Age at smoking  
cessation
Gender FEV1 decline (95% CI)
,30 years Male 
Female
15.5 (11.3–19.8)  
10.4 (6.3–14.5)
30–40 years Male 
Female
24.0 (20.0–28.1) 
16.5 (14.0–19.0)
.40 years Male 
Female
28.9 (26.1–31.1) 
21.0 (18.8–23.2)
Abbreviations: Fev1, forced expiratory volume in 1 second; CI, confidence interval. 
Reprinted with permission of the American Thoracic Society. Copyright © American 
Thoracic Society. Kohansal R, Martinez-Camblor P, Agusti A, Buist AS, Mannino DM, 
Soriano JB. The natural history of chronic airflow obstruction revisited: an analysis of 
the Framingham offspring cohort. Am J Respir Crit Care Med. 2009;180:3–10. Official 
journal of the American Thoracic Society.13International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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Despite initiatives to improve detection and treatment of 
COPD, clinical guidelines are poorly implemented in both 
primary36,37 and secondary care settings.36,38 Diagnosis is 
hampered by very limited use of spirometry within primary 
care because of lack of access and time, cost constraints, 
inaccurate interpretation of results, and inadequately trained 
staff.39,40 A recent study suggested only 30% of patients 
are diagnosed using spirometry according to guideline 
standards.41 Furthermore, evidence suggests that pharma-
cologic therapies are frequently prescribed inappropriately 
and not according to recommendations based on disease 
severity.18,42
Current pharmacologic 
maintenance options
GOLD guidelines advocate a patient-centered, stepwise 
approach to treatment, depending on disease severity 
(Figure 2).1 Intermittent symptoms can be treated with 
short-acting bronchodilators (SABAs). Several drug classes 
are approved for maintenance treatment (ie, medication 
taken regularly to improve symptoms not controlled by 
SABAs). These include anticholinergics (long-acting anti-
muscarinic antagonists [LAMAs]), long-acting β2 agonists 
(LABAs), LABA-inhaled corticosteroid (ICS) combinations, 
methylxanthines (eg, theophylline), and SABAs and their 
combinations (Table 1). The latter (salbutamol [albuterol]) 
either alone or in combination with ipratropium is usually 
reserved for use as rescue medication.
LABAs and LAMAs are currently the preferred phar-
macotherapeutic options for maintenance treatment,1 with 
bronchodilation achieved through different mechanisms 
(Table 1). Currently available long-acting inhaled bron-
chodilators are the once-daily LAMA, tiotropium, and the 
twice-daily LABAs, salmeterol and formoterol. The relative 
benefits of which agent to use first have not been systemati-
cally studied; however, tiotropium is widely used and has 
generally been shown to provide better bronchodilation and 
clinical outcomes than the twice-daily LABAs.43–46 Based on 
current evidence, initial treatment with an LAMA appears to 
be a rational approach, given its ability to reverse the height-
ened cholinergic tone that predominates in COPD patients.15 
LABAs initiate an alternative pathway of bronchodilation.47 
When symptoms are not controlled with monotherapy,   adding 
an LABA to an LAMA “dual” long-acting bronchodilator 
therapy may be more effective than either agent alone, with-
out increased side effects.46,48,49
ICS treatment is not recommended as monotherapy but 
can provide additional benefits, such as reduced exacerbation 
frequency, when combined with LABA therapy in patients 
with moderate and severe COPD and a history of COPD 
I: Mild
FEV1/FVC <0.70
FEV1 ≥80%
predicted
II: Moderate
Active reduction of risk factor(s): influenza, pneumococcal vaccination
Add short-acting bronchodilator (when needed)
Add regular treatment with one or more long-acting bronchodilators
(when needed); add rehabilitation
Add inhaled glucocorticosteroids if repeated
exacerbations
Add long-term oxygen if chronic
respiratory failure. Consider surgical
treatment
FEV1/FVC <0.70
50% ≤FEV1
<80% predicted
III: Severe
FEV1/FVC <0.70
30% ≤FEV1
<50% predicted
IV: Very severe
FEV1/FVC <0.70
FEV1 <30% predicted, or
FEV1 <50% predicted plus chronic
respiratory failure
Figure 2 The stepwise approach to the management of chronic obstructive lung disease.1International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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exacerbations.1,19,49 ICS-LABA combinations have been 
associated with increased risk of pneumonia,19,50,51 with some 
ICS formulations (fluticasone) putatively more likely to be 
associated with pneumonia than others (budesonide).48
LAMA plus LABA plus ICS “triple therapy” may 
have additional clinical benefits and achieve more opti-
mal control in patients with severe COPD, reducing 
dyspnea and rescue medication use,52 providing greater 
improvements in lung function,48,52,53 reducing day- and 
night-time symptoms,48 improving QoL measures,53 and 
reducing exacerbations.48 Although triple therapy is often 
used in patients with severe and very severe COPD, there 
is limited evidence to support the long-term benefits over 
other combination therapy, and cost constraints may limit 
its use in clinical practice.
Methylxanthines, such as theophylline, are reserved as 
third-line options due to their side effect burden, and are only 
recommended for very severe disease.1 At low doses they may 
enhance the anti-inflammatory effects of corticosteroids54 
and hence be useful in combination regimens. Long-term 
oral glucocorticosteroid therapy is not recommended, but 
may be necessary to treat exacerbations in patients with 
severe COPD. Patients with viscous sputum may benefit 
from mucolytic therapy,55 although the overall benefits seem 
small and routine use is not currently recommended. Other 
chronic therapies, such as antioxidants, carbocysteine, and 
N-acetylcysteine, may reduce COPD exacerbations,55–57 but 
evidence is conflicting.58
For inhaled drugs, delivery systems, correct use, and 
patient adherence are important considerations when select-
ing appropriate treatment for individual patients. Inspiratory 
flow rate is important for correct inhaler use, especially in 
patients with severe disease; patients should therefore have 
their technique checked regularly and their flow rate mea-
sured if necessary. Adherence to COPD therapies is poor and 
declines over time,59 which may in part be influenced by the 
inhaler device. At present, there are limited data to suggest an 
advantage for one type of inhaler over another for the drugs 
currently available, although devices that are complicated 
and require coordination between actuation and inhalation 
are less likely to be accepted and used effectively.60
Nonpharmacologic treatment 
options
Although optimal COPD management plans integrate 
both pharmacologic and nonpharmacologic interventions, 
full consideration of the latter is beyond the scope of this 
article. However, effective and evidence-based options, 
including smoking cessation programs, exercise, education, 
vaccination, pulmonary rehabilitation, and management 
of comorbidities should be considered and tailored to the 
individual. Endocrine derangements are common, as is 
Table 1 Current pharmacologic options for the management of COPD1 
Class Agent/s Mode of action Clinical effect
Long-acting  
β2-agonist (LABA)
Salmeterol
Formoterol
•   Stimulate B2-adrenergic receptors  
in airway smooth muscle 
• Cause increased levels of cAMP
•   Increase the rate of ciliary transport  
of mucus
• Decreased mast cell degranulation
•   Bronchodilation by relaxing smooth 
muscle and opening airways 
LAMA Tiotropium • Inhibit muscarinic receptors
• Block the parasympathetic nervous system
• Reduce viscous mucus secretions
•   Act on cholinergic tone, the only reversible 
mechanism of COPD
•   Bronchodilation by reducing 
contraction  
of airway smooth muscle
• Reduce hyperinflation
Methylxanthines  
(phosphodiesterase  
inhibitors)
Theophylline • Phosphodiesterase inhibition
• Raised cAMP
• Limited use due to safety profile
LABA-ICS  
combinations
Formoterol- 
budesonide  
Salmeterol-fluticasone
•   As above plus ICS-associated  
anti-inflammatory effects 
•   Reduce risk of exacerbation in patients   
with severe/very severe disease who  
experience repeated exacerbations
Short-acting LABA-LAMA 
combinations
Fenoterol/ipratropium  
Salbutamol (albuterol)- 
ipratropium
• As above for long-acting agents •   Only indicated as rescue medication 
and not maintenance therapy
•   May be associated with increased risk 
of cardiovascular events
Abbreviations: cAMP, cyclic adenosine monophosphate; COPD, chronic obstructive pulmonary disease; LAMA, long-acting muscarinic antagonist; LABA, long-acting   
β2-agonist; ICS, inhaled corticosteroids.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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cardiovascular disease.61,62 Pulmonary rehabilitation should 
be considered for all patients with COPD and may address 
particular problems, such as exercise deconditioning, relative 
social isolation, altered mood states (especially depression), 
muscle wasting, and weight loss, none of which are addressed 
adequately by current pharmacologic options. Influenza and 
pneumococcal vaccinations are recommended as an impor-
tant risk reduction strategy.1
New and emerging options  
for maintenance treatment
The development of new respiratory medications continues 
and current research focuses on novel once-daily agents 
for administration either as monotherapy or in combination 
with other agents. These include the first once-daily LABA, 
indacaterol, the selective, once-daily, oral phosphodiesterase 
(PDE)-4 inhibitor, roflumilast, and the new, most probably 
twice-daily LAMA, aclidinium.
Indacaterol
Indacaterol was approved for use in the European Union in 
December 2009 for COPD maintenance treatment and, at 
the time of writing, is pending approval in the US. European 
approval was based on data from two pivotal Phase III stud-
ies which showed that indacaterol improved lung function 
(trough FEV1), dyspnea, QoL, and rescue medication use 
compared with placebo (Table 2). Further studies are in 
progress.
The INHANCE (Indacaterol Versus Tiotropium to Help 
Achieve New COPD Treatment Excellence) study was 
a 26-week evaluation of indacaterol 150 µg and 300 µg 
versus placebo and open-label tiotropium in 2059 patients 
with moderate-to-severe COPD.63 Indacaterol was noted to 
be suitable for once-daily dosing, and it was thought that it 
was likely to be “at least as effective as tiotropium for bron-
chodilation and other clinical outcomes such as dyspnea and 
health status”. As the authors note, one of the limitations of 
the study was the open-label comparison, and this needs to 
be borne in mind when interpreting the study results.63
The INVOLVE (Indacaterol: Value in COPD Pulmonary 
Disease: Longer-term Validation of Efficacy and Safety) 
study was a 52-week evaluation of indacaterol 300 µg 
and 600 µg versus placebo and formoterol 12 µg in 1732 
patients with moderate to severe COPD.64 Improvement in 
lung function was noted when compared with formoterol. 
“COPD worsening” was the most common adverse event in 
both studies across active treatment and placebo arms.63,64 No 
differences in mortality rates compared with placebo were 
reported in either study.63,64
Roflumilast
Roflumilast is unique among the PDE inhibitors, having 
selectivity for PDE-4 and no apparent inhibitory effect on 
PDE-3, which has been associated with cardiotoxicity for other 
agents in this class.65 Roflumilast is associated with reduced cel-
lular inflammatory activity, and its therapeutic effects include 
bronchodilation, induction of cytokine and chemokine release 
from inflammatory cells, and inhibition of microvascular leak-
age and cellular trafficking. Clinical studies with roflumilast 
monotherapy demonstrated improved lung function, reduced 
moderate-to-severe exacerbations, reduced requirement for anti-
inflammatory/anti-infective medications, and improved QoL 
measures (Table 2).66,67 Similarly, improvements in lung func-
tion and exacerbation outcomes were reported when roflumilast 
was added to tiotropium, or to salmeterol plus fluticasone.68 
Notable side effects with roflumilast include headache, weight 
loss (2.5 kg in all studies at six months and one year), diarrhea, 
nausea, and stomach ache (ie, gastrointestinal side effects that 
resulted in a significant early study withdrawal rate).66–68
Approvals for roflumilast are pending; however, it has 
been recommended for approval in Europe by the Commit-
tee for Medicinal Products for Human Use as maintenance 
treatment as an “add-on” to bronchodilator therapy in patients 
with severe COPD (FEV1 ,50% predicted) and a history of 
chronic sputum production and exacerbations.69
Aclidinium
Aclidinium is currently in an earlier stage of clinical devel-
opment than indacaterol and roflumilast. To date, clinical 
studies have demonstrated a bronchodilatory effect and 
an improvement in QoL versus placebo in patients with 
moderate-to-severe COPD, and an acceptable tolerability 
profile.70 Preclinical studies suggest a potential for reduced 
class-related adverse effects with this agent, although 
  confirmation from large-scale clinical trials is awaited.
A number of outstanding questions remain to be answered 
before the place of indacaterol, roflumilast, and aclidinium 
in current treatment strategies can be determined. The design 
of the INHANCE indacaterol study, in which tiotropium was 
given as open-label therapy, limits the conclusions that can 
be drawn from these data with regard to the relative efficacy 
of these agents, and additional data are required from studies 
that are well controlled. Tolerability issues with roflumilast 
may limit its use in some patients.66–68International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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Table 2 emerging therapies for COPD
Study Efficacy findings Safety findings Reference(s)
Indacaterol
INHANCe 
26 weeks, indacaterol 150 µg and  
300 µg versus placebo and open-label 
tiotropium in moderate-to-severe  
COPD 
(n = 2059; 77% completed study)
Indacaterol improved Fev1,  
dyspnea, and quality of life,  
and reduced use of rescue  
medications, and exacerbations  
versus placebo
Noninferiority to tiotropium
Adverse events: Similar incidences in all  
treatment groups (64%–67%); most common  
were COPD worsening (18%–22%) and upper  
RTI (7%–8%). Higher incidence of cough  
occurring within five minutes of indacaterol  
administration (17%–21% versus 0.8%  
and 2.4% for tiotropium and placebo,  
respectively). This did not increase study 
discontinuation rates, and cough as an  
adverse event did not differ across treatment 
groups. Mortality: Three deaths (indacaterol 
150 µg, n = 1; tiotropium, n = 2), none related  
to treatment
Donohue et al63
INvOLve 
52 weeks, indacaterol 300 µg and  
600 µg versus placebo and formoterol  
12 µg in moderate-to-severe COPD 
(n = 1732; 74% completed study)
Indacaterol improved Fev1,  
dyspnea, day and night symptoms,  
QoL, delayed time to exacerbation,  
and reduced use of rescue  
medications
Adverse events: Similar incidences among  
treatment groups (62%–71%); most common  
(occurring .10% patients) were COPD  
worsening (28%–35%) and nasopharyngitis  
(13%–19%). Higher incidence of cough  
occurring within five minutes of indacaterol 
administration (19% versus 0.8% and 1.8%  
for formoterol and placebo, respectively).  
This did not increase study  
discontinuation rates.
Mortality: eight deaths during treatment  
(indacaterol 350 µg, n = 1; formoterol,  
n = 3; placebo, n = 4); the indacaterol  
death (cardiac arrest) suspected to be  
related to treatment (patient discontinued  
due to dyspnea).
Dahl et al64
Roflumilast
M2–124 and M1–125 
52 weeks, identical studies performed  
in 10 and 8 countries, respectively.  
Assessed roflumilast 500 µg once daily  
versus placebo in symptomatic  
moderate-to-severe COPD 
(total n = 3091)
Combined results of M2–124  
and M2–125:
Roflumilast improved FEV1,  
dyspnea, and reduced  
exacerbations; there were no  
differences in QoL
Adverse events: Higher rate with  
roflumilast versus placebo  
(67% versus 62%)
Greater weight loss observed with  
roflumilast.
Mortality: Similar rates between  
treatment arms (2% in both)
Calverley et al66
M2–127 
24 weeks, roflumilast 500 µg or  
placebo plus salmeterol in moderate- 
to-severe COPD 
(total n = 933)
Salmeterol + roflumilast versus  
salmeterol + placebo
Addition of roflumilast improved  
Fev1 and reduced the frequency  
of exacerbations. There were no  
differences in dyspnea, QoL, or  
rescue medication use
Adverse events: weight loss, diarrhea, and  
nausea were more frequently observed in  
salmeterol + roflumilast group
withdrawals: More withdrawals occurred  
in the salmeterol + roflumilast versus  
salmeterol + placebo group
 
Fabbri et al68
M2–128 
24 weeks, roflumilast 500 µg  
or placebo plus tiotropium in  
moderate-to-severe  
symptomatic COPD 
(total n = 933)
Tiotropium + roflumilast versus  
tiotropium + placebo
Addition of roflumilast improved  
Fev1, QoL, and dyspnea and  
reduced rescue medication  
use. There were no reductions  
in exacerbations
Adverse events: weight loss, diarrhea,  
and nausea were more frequently observed  
in tiotropium + roflumilast group
Fabbri et al68
Abbreviations: COPD, chronic obstructive pulmonary disease; Fev1, forced expiratory volume in one second; RTI, respiratory tract infection; QoL, quality of life.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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Moving forward:  advances  
in optimal management
COPD is a chronic illness requiring long-term treatment. The 
clinical aim of maintenance therapy focuses on controlling 
symptoms and reducing exacerbation   frequency.1 Recent 
data suggest that maintenance bronchodilator therapy may 
contribute to slowing the rate of lung function decline 
in symptomatic patients with COPD, raising the poten-
tial for disease-course modification through ongoing 
pharmacotherapy.
The first suggestion that long-term bronchodilator therapy 
might slow FEV1 decline in COPD patients came from a 
post hoc analysis of 12-month data from two double-blind, 
randomized, placebo-controlled tiotropium trials.71 The mean 
annual decline in FEV1 was 12 mL versus 58 mL (P = 0.005) 
among patients receiving tiotropium versus placebo (SABAs 
only) as maintenance therapy. The potential for maintenance 
bronchodilator therapy to modify the clinical course of COPD 
has now been examined in a systematic manner in two large-
scale, long-term clinical studies, ie, UPLIFT® (Understanding 
Potential Long-term Impacts on Function with Tiotropium)72 
and TORCH (Towards a Revolution in COPD Health).50 
Patients in TORCH were randomized to salmeterol and fluti-
casone propionate (either as monotherapy or in combination), 
and were permitted use of SABAs and oral corticosteroids to 
treat exacerbations. Patients in UPLIFT were randomized to 
tiotropium or placebo and were permitted use of any respira-
tory medications except inhaled anticholinergics.
The value of long-term maintenance therapy with bron-
chodilators in COPD is confirmed by the efficacy, mortality, 
and safety data from UPLIFT and TORCH (Tables 3 and 4, 
Figure 3). Although UPLIFT did not meet its primary end-
point of pre- and postbronchodilator rate of FEV1 decline, 
the study did demonstrate significantly greater lung function 
improvements with tiotropium versus placebo at all time 
points throughout the trial.72 In the TORCH study, lung func-
tion was a secondary endpoint, and treatment with salmeterol, 
fluticasone, or a combination of salmeterol and fluticasone 
was shown to reduce the rate of lung function decline sig-
nificantly compared with placebo (Figure 3a, Table 3).73 
Absolute changes in lung function in UPLIFT and TORCH 
were determined using different methodologies. For TORCH, 
the mean postbronchodilator values were determined fol-
lowing salbutamol 400 µg. It is unclear whether the study 
drug was administered prior to testing. Study group differ-
ences in FEV1 relative to placebo were 42 mL (salmeterol), 
47 mL (fluticasone), and 92 mL (combination). Morning 
predose (trough) values were not measured in TORCH. For 
UPLIFT, morning trough differences (tiotropium versus 
placebo) ranged from 87 to 103 mL, and therefore represent 
the 24-hour effect of tiotropium. In UPLIFT, both treatment 
groups were sequentially administered salbutamol 400 µg 
and ipratropium 80 µg in addition to the study drug in order 
to achieve maximal bronchodilation in both groups. Despite 
both groups having eight actuations of short-acting broncho-
dilators, treatment group differences in postbronchodilator 
FEV1 of 47 to 65 mL were still observed. However, the dif-
ferences in spirometry protocols render comparisons between 
the two trials invalid.
The primary endpoint of achieving a significant decrease 
in mortality among patients treated with combination therapy 
versus placebo was not reached in TORCH.15 However, both 
TORCH and UPLIFT demonstrated the potential to reduce 
exacerbation frequency significantly with bronchodilator 
maintenance therapy (Table 3, Figure 3b). This finding is 
of considerable importance for all COPD patients with 
more advanced disease, given recent data indicating het-
erogeneity in terms of symptomatic recovery from acute 
COPD exacerbations and the potential of exacerbations to 
contribute to disease progression.31,34 In both the UPLIFT 
and TORCH studies, statistically significant improvements 
in QoL (St George’s Respiratory Questionnaire total scores) 
were observed with all active treatments versus placebo 
(except salmeterol monotherapy in TORCH), although these 
improvements were not clinically significant (Figure 3c).50,72 
In UPLIFT, a greater proportion of patients in the tiotropium 
group than in the placebo group achieved a clinically signifi-
cant improvement of $4 units on the St George’s Respiratory 
Questionnaire total score.72
UPLIFT and TORCH have also contributed important 
information about COPD patients in terms of common 
comorbidities, smoking status, and concomitant medications, 
in addition to patient characteristics that might influence the 
rate of FEV1 decline. For example, a more rapid FEV1 decline 
was reported in patients with a lower body mass index and in 
younger (,55 years) compared with older patients, the latter 
observation being consistent with the recent Framingham 
Cohort Study reports.13 Bronchodilator responsiveness was 
found to be far more common in COPD than previously 
recognized and did not impact either the short- or long-term 
responses to bronchodilator treatment.72,74
Treating patients earlier  
in the disease course
The potential for disease-course modification with long-term 
maintenance therapy is perhaps the single most encouraging International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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outcome from the UPLIFT and TORCH studies in terms of 
improving prognosis. To date, only smoking cessation has 
been shown to change the clinical course of COPD,75 although 
long-term oxygen therapy leads to a survival advantage,76 
and pulmonary rehabilitation has been shown to improve 
dyspnea and exercise capacity and to reduce exacerbation 
rate and severity.16
Data from both studies indicate the potential to slow the 
rate of lung function decline and thus change the clinical 
course of disease for patients diagnosed and treated early. 
Post hoc and subgroup analyses have shown that initiating 
maintenance treatment at earlier disease stages can have a 
greater impact than introducing treatment at later stages 
with respect to improvements in QoL, reduction in risk/
frequency of exacerbations, improving lung function, and 
potentially reducing mortality (Table 5).18,19,77,78 Both studies 
demonstrated a slower rate of FEV1 decline compared with 
placebo for patients with GOLD Stage II disease. In UPLIFT, 
significant benefits in disease progression and QoL were 
observed in patients who were maintenance-treatment-naïve 
at study initiation,78 and those aged #50 years.77 The effects 
of maintenance pharmacotherapy in early-stage disease need 
to be rigorously investigated in well designed, prospective 
studies.
Implications for future COPD 
management
In order for the full benefit of the findings from the UPLIFT 
and TORCH studies to be incorporated into clinical practice, 
it is necessary to identify early-stage patients. This will 
require heightened COPD awareness among both patients and 
physicians. A major barrier to early detection is that patients 
often do not recognize the early symptoms, or consider them 
a consequence of aging or smoking.
Spirometry that is performed and interpreted properly 
is a critical step in the accurate diagnosis of COPD, as is 
the collection/assessment of patient-reported outcomes and 
health status, including smoking history, occupation (past 
and present), daily symptoms (eg, breathlessness, cough, 
sputum production), activity limitation, and other disease 
Table 4 UPLIFT and TORCH safety and mortality summary50,72,73 
Arm Mortality Safety
Reduction in risk of  
death (versus control)a
Adverse events 
(% patients)
Serious adverse events  
(% patients)
Most common adverse events   
(incidence rate/year)b
UPLIFT
Tiotropium  
(n = 2986)
11% (NS)c 
13%d
92.6 51.6 COPD exacerbations (0.38)
Control  
(n = 3006)
– 92.3 50.2 COPD exacerbations (0.46)
TORCH
Salmeterol alone  
(n = 1521)
12% (NS) 90 40 COPD exacerbations (0.76) 
Nasopharyngitis (0.09) 
Upper RTI (0.08) 
Headache (0.06)
ICS alone  
(n = 1534)
–6% (NS) 90 42 COPD exacerbations (0.78) 
Nasopharyngitis (0.10) 
Upper RTI (0.09) 
Pneumonia (0.07)f 
Headache (0.06)
SFC  
(n = 1533)
18% (NS)e 89 43 COPD exacerbations (0.67) 
Upper RTI (0.11) 
Nasopharyngitis (0.10) 
Pneumonia (0.07)fg
Control  
(n = 1524)
– 90 43 COPD exacerbations (0.92) 
Nasopharyngitis (0.09) 
Headache (0.08)
Notes: aReductions in risk of death were based on hazard ratios; badverse events with incidence rates of .0.05 per year; cper protocol analysis versus control. For UPLIFT, 
this was intent-to-treat +30-day washout and for TORCH this was ITT (no washout); the results were not statistically significant for both studies (P = 0.09 for UPLIFT;   
P = 0.052 for SFC in TORCH); dfor comparison, the ITT (no washout) results for UPLIFT are shown, for which the result was statistically significant; eadjusted for interim 
analyses; fstatistically significant increase versus control; gstatistically significant increase versus salmeterol. 
Abbreviations: NS, not significant; COPD, chronic obstructive pulmonary disease; RTI, respiratory tract infection; ICS, inhaled corticosteroid; SFC, salmeterol plus 
fluticasone propionate; ITT, intent to treat; TORCH, Towards a Revolution in COPD Health; UPLIFT, Understanding Potential Long-term Impacts on Function with 
Tiotropium.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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Figure 3 Impact of maintenance bronchodilation on A) the rate of decline in lung function, B) exacerbations, and C) quality of life.50,72,73
Notes: A) *P < 0.003 versus placebo; †P f< 0.001 versus; B) *P < 0.001 versus control; †P < 0.02 versus salmeterol; ‡P < 0.02 versus fluticasone; C) *P < 0.001 versus control.
Abbreviation: TORCH, Towards a Revolution in COPD Health; UPLIFT, Understanding Potential Long-term Impacts on Function with Tiotropium; Fev1, forced expiratory 
volume in one second; SGRQ, St George’s Respiratory Questionnaire; NS, nonsignificant versus control.
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manifestations. Improved identification of patients at risk 
for developing COPD, based on recognized risk factors 
and symptoms, is required to enable early diagnosis and to 
initiate prompt maintenance treatment. Diagnostic tools and 
questionnaires (eg, St George’s Respiratory Questionnaire, 
Chronic Respiratory Questionnaire) can facilitate clinical 
assessment; however, their length precludes practical appli-
cation in everyday practice. Two shortened and simplified 
COPD screening tools may be more suited to clinical settings 
and for the general public, ie, the COPD Assessment Test79 
and the self-administered COPD Population Screener.80 
These tools may help to identify patients likely to have COPD, 
but further evaluation and validation is required to confirm 
their usefulness in clinical practice.
Programs to educate both physicians and patients are also 
necessary to increase vigilance for early signs and symptoms, 
including increased recognition that COPD is not restricted 
to the elderly but can also affect younger people in their 30s 
and 40s,81 and removal of the nihilistic attitude that COPD 
is a self-inflicted disease. Improved adherence to treatment 
guidelines, including correct implementation of spirometry, 
is also required.
Conclusion
The emergence of scientific evidence from multiple sources, 
including large clinical trials, has expanded our knowledge 
of COPD and fuelled a shift in our understanding of lung 
function decline and disease progression. Coupled with the 
emergence of a range of new drug treatments with differ-
ing mechanisms of action targeting different physiologic 
aspects of the disease, the first decade of this new century has 
become an exciting period in COPD management. The current 
challenge is to apply our understanding of disease processes 
to the design of optimal treatment algorithms for maintenance 
therapy, encompassing both established and emerging drug 
treatments. Landmark clinical trial data reinforce when foun-
dation maintenance therapy should be introduced for symp-
tomatic patients with COPD and its long-term health benefits. 
Finally, emerging evidence supports the early introduction of 
pharmacotherapies that relieve breathlessness, with the aim of 
slowing lung function decline and reducing the risk of acute 
exacerbations. However, further studies are required before 
evidence-based guidelines are able to assess adequately the 
potential of treatment for early-stage disease.
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